Use of GLP-1 or analogs in treatment of myocardial infarction
US6747006B2 · kind B2 · utility
84Cited by
6References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 12, 2001 |
| Grant date | Jun 8, 2004 |
| Priority date | — |
| Expiry date | Apr 12, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.